Basic Information
| RNALocate ID: | RLID:11003019 |
| RNA Symbol: | hsa-miR-181d-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-181d |
| RNA ID: | miRBase:MIMAT0002821 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 21505438 |
| Tissue/Cell Line: | Jurkat-derived T cell line (J77cl20) |
| Method: | Microarray |
| Description: | Microarray analysis of exosomal miRNAs verses the miRNAs of their respective donor cells. Data are collected from Supplementary Data 1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002349 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:11003020 | Exosome | Brain tissue | 23382797 |
| RLID:11003021 | Exosome | Plasma | 23663360 |
| RLID-D:11000156 | Exosome | Blood | |
| RLID-D:11000488 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-181d-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-20114 |
| MNDR | hsa-miR-181d-5p | Medulloblastoma | MNDR-E-MI-20115 |
| MNDR | hsa-miR-181d-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-20116 |
| MNDR | hsa-miR-181d-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-20117 |
| MNDR | hsa-miR-181d-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-20118 |
| MNDR | hsa-miR-181d-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-20119 |
| MNDR | hsa-miR-181d-5p | Her2-receptor positive breast cancer | MNDR-E-MI-20120 |
| MNDR | hsa-miR-181d-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-20121 |
| MNDR | hsa-miR-181d-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-20122 |
| MNDR | hsa-miR-181d-5p | Small intestine cancer | MNDR-E-MI-20123 |
| MNDR | hsa-miR-181d-5p | Prostate cancer | MNDR-E-MI-20124 |
| MNDR | hsa-miR-181d-5p | Gastric cancer | MNDR-E-MI-20125 |
| MNDR | hsa-miR-181d-5p | Alzheimer disease | MNDR-E-MI-20126 |
| MNDR | hsa-miR-181d-5p | Bladder cancer | MNDR-E-MI-20127 |
| MNDR | hsa-miR-181d-5p | Head and neck cancer | MNDR-E-MI-20128 |
| MNDR | hsa-miR-181d-5p | Leukemia | MNDR-E-MI-20129 |
| MNDR | hsa-miR-181d-5p | Huntington disease | MNDR-E-MI-20130 |
| MNDR | hsa-miR-181d-5p | Chorea | MNDR-E-MI-20131 |
| MNDR | hsa-miR-181d-5p | Cardiovascular disease | MNDR-E-MI-20132 |
| MNDR | hsa-miR-181d-5p | Lung cancer | MNDR-E-MI-20133 |
| MNDR | hsa-miR-181d-5p | Fragile x syndrome | MNDR-E-MI-20134 |
| MNDR | hsa-miR-181d-5p | Parkinson disease | MNDR-E-MI-20135 |
| MNDR | hsa-miR-181d-5p | Breast cancer | MNDR-E-MI-20136 |
| MNDR | hsa-miR-181d-5p | Pancreatic cancer | MNDR-E-MI-20137 |
| MNDR | hsa-miR-181d-5p | Melanoma | MNDR-E-MI-20138 |
| MNDR | hsa-miR-181d-5p | Rectum adenocarcinoma | MNDR-E-MI-20139 |
| MNDR | hsa-miR-181d-5p | Nephroblastoma | MNDR-E-MI-20140 |
| MNDR | hsa-miR-181d-5p | Colon cancer | MNDR-E-MI-20141 |
| MNDR | hsa-miR-181d-5p | Colon adenocarcinoma | MNDR-E-MI-20142 |
| MNDR | hsa-miR-181d-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-20143 |
| MNDR | hsa-miR-181d-5p | Familial ovarian cancer | MNDR-E-MI-20144 |
| MNDR | hsa-miR-181d-5p | Prostate adenocarcinoma | MNDR-E-MI-20145 |
| MNDR | hsa-miR-181d-5p | Carcinoma ductal breast | MNDR-E-MI-20146 |
| MNDR | hsa-miR-181d-5p | Glioblastoma | MNDR-E-MI-20147 |
| MNDR | hsa-miR-181d-5p | Glioma | MNDR-E-MI-20148 |
| MNDR | hsa-miR-181d-5p | Nemaline myopathy | MNDR-E-MI-20149 |
| MNDR | hsa-miR-181d-5p | Epilepsy temporal lobe | MNDR-E-MI-20150 |
| MNDR | hsa-miR-181d-5p | Osteosarcoma | MNDR-E-MI-20151 |
| MNDR | hsa-miR-181d-5p | Breast carcinoma | MNDR-E-MI-20152 |
| MNDR | hsa-miR-181d-5p | Cervical squamous cell carcinoma | MNDR-E-MI-20153 |
| MNDR | hsa-miR-181d-5p | Lung squamous cell carcinoma | MNDR-E-MI-20154 |
| MNDR | hsa-miR-181d-5p | Thyroid carcinoma | MNDR-E-MI-20155 |
| MNDR | hsa-miR-181d-5p | Ovarian carcinoma | MNDR-E-MI-20156 |
| MNDR | hsa-miR-181d-5p | Pancreatic adenocarcinoma | MNDR-E-MI-20157 |
| MNDR | hsa-miR-181d-5p | Carcinoma renal cell | MNDR-E-MI-20158 |
| MNDR | hsa-miR-181d-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-20159 |
| MNDR | hsa-miR-181d-5p | Clear cell renal cell carcinoma | MNDR-E-MI-20160 |
| MNDR | hsa-miR-181d-5p | Cholangiocarcinoma | MNDR-E-MI-20161 |
| MNDR | hsa-miR-181d-5p | Esophageal cancer | MNDR-E-MI-20162 |
| MNDR | hsa-miR-181d-5p | Lung small cell carcinoma | MNDR-E-MI-20163 |
| MNDR | hsa-miR-181d-5p | Synovial sarcoma | MNDR-E-MI-20164 |
| MNDR | hsa-miR-181d-5p | T acute lymphoblastic leukemia | MNDR-E-MI-20165 |
| MNDR | hsa-miR-181d-5p | Acute t cell leukemia | MNDR-E-MI-20166 |
| MNDR | hsa-miR-181d-5p | Breast invasive carcinoma | MNDR-E-MI-20167 |
| MNDR | hsa-miR-181d-5p | Hepatocellular carcinoma | MNDR-E-MI-20168 |
| MNDR | hsa-miR-181d-5p | Familiar ovarian carcinoma | MNDR-E-MI-20169 |
| MNDR | hsa-miR-181d-5p | Rheumatoid arthritis | MNDR-E-MI-20170 |
| MNDR | hsa-miR-181d-5p | Neuromyelitis optica | MNDR-E-MI-20171 |
| MNDR | hsa-miR-181d-5p | Acute myelocytic leukemia | MNDR-E-MI-20172 |
| MNDR | hsa-miR-181d-5p | Colorectal cancer | MNDR-E-MI-20173 |
| MNDR | hsa-miR-181d-5p | Nasopharynx carcinoma | MNDR-E-MI-20174 |
| MNDR | hsa-miR-181d-5p | Multiple myeloma | MNDR-E-MI-20175 |
| MNDR | hsa-miR-181d-5p | Nasopharyngeal cancer | MNDR-E-MI-20176 |
| MNDR | hsa-miR-181d-5p | Epstein-barr virus infections | MNDR-E-MI-20177 |
| MNDR | hsa-miR-181d-5p | Stroke | MNDR-E-MI-20178 |
| MNDR | hsa-miR-181d-5p | Non-alcoholic fatty liver disease | MNDR-E-MI-20179 |
| MNDR | hsa-miR-181d-5p | HPV | MNDR-E-MI-20180 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | BCL2 | Homo sapiens | RR00219009 |
TOP